<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705990</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI S001</org_study_id>
    <nct_id>NCT01705990</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers</brief_title>
  <official_title>A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and immunogenicity of
      Sendai HIV vaccine SeV-G(NP) given intranasally and Ad35-GRIN administered intramuscularly in
      prime-boost regimens in HIV-uninfected, healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double-blind, placebo-controlled, dose-escalation trial assessing
      the safety, tolerability, and immunogenicity of SeV-G(NP) given intranasally by drops and
      Ad35-GRIN administered intramuscularly in each of four prime-boost regimens.

      Volunteers will be screened up to 42 days before the 1st vaccination and will be followed for
      12 months after the last vaccine administration (16 months after the first vaccination). It
      is anticipated that it will take approximately 6 months to enroll the study. Approximately 64
      volunteers (48 vaccine and 16 placebo recipients) will be included in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>16 months approximately</time_frame>
    <description>To evaluate the safety and tolerability of SeV-G(NP) and Ad35-GRIN administered in four prime-boost regimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Shedding</measure>
    <time_frame>16 months</time_frame>
    <description>To assess the presence and persistence of the SeV-G(NP) vector and the in vivo genetic integrity of the insert</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>16 months</time_frame>
    <description>To assess (qualitative and quantitative) immune responses elicited by the different prime-boost regimens.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Ad35-GRIN followed by SeV-G(NP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: SeV-G(NP) only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SeV-G(NP) (0.2mL, 2x10^7 CIU)</intervention_name>
    <description>Delivered intranasally by drops</description>
    <arm_group_label>Group A: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SeV-G(NP) (0.2mL, 2x10^8 CIU)</intervention_name>
    <description>Delivered intranasally by drops</description>
    <arm_group_label>Group B: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
    <arm_group_label>Group C: Ad35-GRIN followed by SeV-G(NP)</arm_group_label>
    <arm_group_label>Group D: SeV-G(NP) only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35-GRIN (0.5mL)</intervention_name>
    <description>(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection</description>
    <arm_group_label>Group A: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
    <arm_group_label>Group B: SeV-G(NP) followed by Ad35-GRIN</arm_group_label>
    <arm_group_label>Group C: Ad35-GRIN followed by SeV-G(NP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male or female adults,

          -  18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),

          -  who do not report high-risk behaviour for HIV infection,

          -  who are available for the duration of the trial,

          -  who are willing to undergo HIV testing,

          -  use an effective method of contraception, and

          -  who, in the opinion of the principal investigator or designee, understand the study
             and who provide written informed consent.

        Exclusion Criteria:

          -  confirmed HIV infection,

          -  pregnancy and lactation,

          -  significant acute or chronic disease,

          -  clinically significant laboratory abnormalities,

          -  recent vaccination or receipt of a blood product,

          -  previous receipt of an HIV vaccine, and

          -  previous severe local or systemic reactions to vaccination or history of severe
             allergic reactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project San Francisco</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Stephen's Centre</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Rwanda</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.iavi.org</url>
    <description>International AIDS Vaccine Initiative</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>August 25, 2015</last_update_submitted>
  <last_update_submitted_qc>August 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>HIV vaccine</keyword>
  <keyword>HIV prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

